RESUMEN
A child with persistent runny nose may cause significant parental anxiety and healthcare utilisation. While the most common diagnoses are recurrent acute viral upper respiratory tract infections and allergic rhinitis, a careful history and examination is necessary to exclude other causes and to identify comorbidities. Treatment can then be tailored to the underlying cause. The aim of this article is to provide a systematic approach to such patients.
RESUMEN
Betaine therapy was given for 2 years to a 2-year-old boy with 5,10-methylenetetrahydrofolate reductase deficiency. Used as a methyl donor to lower homocysteine levels through methylation of methionine, betaine has been reported to be effective in treating homocystinuria. Satisfactory biochemical and clinical responses were obtained with the following regimen: betaine started in the newborn period at increasing doses to reach 1 g given six times a day. It is suggested that frequent administration of a moderate dose may provide clinical and biochemical benefit.
Asunto(s)
5,10-Metilenotetrahidrofolato Reductasa (FADH2)/deficiencia , Betaína/administración & dosificación , Deficiencia de Ácido Fólico/tratamiento farmacológico , 5,10-Metilenotetrahidrofolato Reductasa (FADH2)/sangre , Preescolar , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Deficiencia de Ácido Fólico/enzimología , Estudios de Seguimiento , Homocisteína/sangre , Homocisteína/efectos de los fármacos , Humanos , Lipotrópicos/administración & dosificación , Masculino , Factores de TiempoRESUMEN
Acquired partial lipodystrophy (Barraquer-Simons syndrome) is a rare condition with onset in childhood, and it is characterized by progressive loss of subcutaneous fat in a cephalocaudal fashion. Although it is known that acquired partial lipodystrophy usually follows acute febrile illness, it is very rarely reported to occur in association with varicella. In this case report, we present a seven-year-old girl with progressive loss of fat in her face just after varicella who was diagnosed as acquired partial lipodystrophy.
Asunto(s)
Tejido Adiposo/patología , Varicela/complicaciones , Lipodistrofia/etiología , Varicela/diagnóstico , Niño , Diagnóstico Diferencial , Electromiografía , Femenino , Humanos , Lipodistrofia/diagnósticoRESUMEN
OBJECTIVE: The aim of this study was to evaluate the clinical course of Hashimoto's thyroiditis (HT) in children and adolescents and the effects of levothyroxine therapy on the clinical course and laboratory findings. METHODS: The clinical and laboratory data of 101 patients with HT at presentation and during a three-year follow-up period were retrospectively evaluated using patient records. RESULTS: The mean age of the patients at the time of diagnosis was 12.3 ± 2.90 years and female/male ratio was 5.7/1. The complaint at the time of hospital presentation was goiter in 57.8% of the patients. At baseline, 36.7% of the patients were euthyroid, whereas 32.7% had subclinical hypothyroidism, 16.6 % of subjects were evaluated as hypothyroid. Twelve of the 28 patients who were initially euthyroid and not receiving therapy developed subclinical or overt hypothyroidism during the first 18 months of the follow-up period and were started on thyroid medication. At presentation, the mean anti-thyroglobulin (anti-Tg) and anti-thyroperoxidase antibody levels were 450 ± 725 IU/mL and 392 ± 428 IU/mL, respectively and at the end of the follow-up period, a significant decrease was observed in the anti-Tg levels of patients receiving levothyroxine from the beginning. CONCLUSIONS: Thyroid functions of the patients with HT should be monitored periodically for hypothyroidism. Levothyroxine therapy may positively affect the clinical course of the disease and the antibody titers.
Asunto(s)
Enfermedad de Hashimoto/tratamiento farmacológico , Tiroxina/uso terapéutico , Adolescente , Autoanticuerpos/sangre , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Enfermedad de Hashimoto/inmunología , Humanos , Yoduro Peroxidasa/inmunología , Masculino , Estudios RetrospectivosRESUMEN
Autoimmune hemolytic anemia with giant cell hepatitis is a distinct entity in children. It is usually fatal with progressive liver disease. Immunosuppressive treatment with conventional drugs offers some response; however, it is usually only temporary. Alternative therapeutic options with monoclonals have been reported with promising remission of the disease. We report a case with autoimmune hemolytic anemia+giant cell hepatitis after varicella infection. She was resistant to standard immunosuppressive combinations, and rescue therapy with rituximab was used. Remission was not achieved with the drug and the child died with septic complication.